hrp0094fc9.4 | Growth Hormone and IGFs | ESPE2021

Optimising adherence using a connected injection device can improve growth outcomes: Evidence from real-world data on 11 million injections in 20,000 patients with growth disorders

Koledova Ekaterina , Bagha Merat , Arnaud Lilian , Piras Francesco , van Dommelen Paula ,

Background: For early identification of patients requiring adherence support, objective, real-time adherence data are needed. The easypod™ electromechanical injection device, in combination with the easypod™ connect ecosystem, electronically records and transmits, in real time, accurate records of the date, time and dose injected for patients receiving recombinant human growth hormone (r-hGH) to treat growth disorders. Healthcare professionals can us...

hrp0094p2-250 | Growth hormone and IGFs | ESPE2021

Patterns of suboptimal adherence to growth hormone treatment in children living in Italy

Centonze Chiara , van Dommelen Paula , Tornicasa Vincenzo , Koledova Ekaterina , Loche Sandro ,

Background: Monitoring adherence to growth hormone (GH) treatment is important, because poor adherence can lead to suboptimal clinical outcomes. The easypod™ electromechanical injection device in combination with the web-based easypod™ connect platform electronically records and transmits accurate, objective records of the date, time and dose injected of patients receiving GH with growth disorders, allowing physicians to accurately monitor patients&#...

hrp0097p1-239 | Diabetes and Insulin | ESPE2023

Epidemiology of Type 1 Diabetes among children under 15 years of age in Navarre (Northern Spain) between 2012-2022

J. Chueca Maria , Berrade Sara , Andres Carlos , Elcano Leire , Bello Paula , Burillo Elisabet

The incidence of TIDM varies greatly between different countries and regions. In Navarre, located in the north of Spain, at the western end of the Pyrenees, there has been a clear increase in the incidence of TIDM, from 13,5 cases per 100000 in the decade 1990-2000 to 20,1 cases per 100000 between 2006-2011. We wonder if this upward trend has continued in recent years. Our hospital is a reference center for Pediatric Endocrinology in Navarre.Obje...

hrp0097p1-102 | GH and IGFs | ESPE2023

Assessment of clinical pediatric perception of short stature in childhood and challenges to treat with Growth Hormone in Brazil: A exploratory evaluation of a developing country daily practice.

Barquero Paula , Aranha Pedro , Souza Leonardo , Careli Guilherme , Veçoso Marcos , Freire Daniel , Sato Cleber

Background: Concerns about a child's growth are one of the most common topics parents express during pediatric visits and are a leading cause for referral to a pediatric endocrinologist. For the general pediatric, when short stature is diagnosed, its clinical management remains a challenge.Objective: The aim of the study was to approach and understand the perception from the general pediatrician about short stature,...

hrp0097p1-288 | GH and IGFs | ESPE2023

The Growzen™ buddy smartphone application shows positive findings on adherence in Argentinian patients receiving growth hormone therapy for growth disorders

van Dommelen Paula , Arnaud Lilian , Assefi Aria , Lourdes Crespo Maria , Koledova Ekaterina

Background: Digital health solutions, such as the Growzen™ buddy smartphone application (app), can facilitate adherence to recombinant human growth hormone (r-hGH) treatment for patients with growth disorders. The app alerts patients when it’s time for an injection and allows patients and their caregivers to self-monitor growth, to build a routine and improve adherence. The app also contains educational resources to empower patients to be active in...

hrp0097p1-149 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Evaluation of new cutt-off points of the LHRH stimulation test in the diagnosis of central precocious puberty

Valls Llussà Aina , Murillo Vallés Marta , Martinez Couselo Silvia , Sol Ventura Paula

Introduction: Central precocious puberty (PPC) is defined by the appearance of sexual characters at a chronological age lower than -2.5DS of the average for the reference population. Diagnostic is clinical but the hormonal assessment is essential. Basal gonadotropin values are not enough for the diagnosis. Gonadotropin-releasing hormone (GnRH) stimulation tests evidence the activation of the hypothalamic-pituitary-gonadal axis, however there is controversy abo...

hrp0098p1-44 | Fat, Metabolism and Obesity 1 | ESPE2024

Assessment of metabolomic-nutritional status and cardiovascular risk in adolescents with anorexia nervosa and low body weight

Sol Ventura Paula , Siurana Jose , Yeste Diego , Feliu Albert , Bosch Zelmira , Amigo Nuria

Introduction: There is a close relationship between cardiovascular disease and diet. While cardiometabolic risk has been demonstrated in adolescents with obesity, there is little information on the advanced lipoprotein profile (ALP) in adolescents with anorexia nervosa and low body weight.Objective: To evaluate the metabolomic-nutritional and cardiac profile in three groups of adolescents: 1. anorexia nervosa and low bod...

hrp0098p1-153 | GH and IGFs 2 | ESPE2024

Enhancing growth hormone treatment adherence in Argentina: A patient support programme approach

Reza Assefi Aria , Lourdes Crespo Maria , Chiarpenello Javier , van Dommelen Paula , Debicki Matías , Koledova Ekaterina

Background: Numerous studies have highlighted the importance of measuring and achieving optimal adherence to growth hormone treatment in patients with growth disorders. However, there is still a paucity of research on how treatment adherence can be improved in patients with suboptimal adherence.Aim: To classify the causes of suboptimal adherence and collaborate with patients and caregivers to improve adherence.<p cla...

hrp0098p1-154 | GH and IGFs 2 | ESPE2024

Growth chart with cut-offs for poor growth response to growth hormone therapy using worldwide data in patients with growth hormone deficiency and small for gestational age

van Dommelen Paula , Loche Sandro , De Arriba Munoz Antonio , Koledova Ekaterina

Background: Several criteria for growth response to growth hormone (GH) therapy have been developed. These include height velocity (HV), height standard deviation score (HSDS), ΔHV, and ΔHSDS. Other parameters considered as predictors of growth response include age at start, weight SDS, GH dose, and target height SDS. Among these, the two most important parameters to predict future height before treatment start are HSDS and age.<p class="abstex...

hrp0098p2-150 | GH and IGFs | ESPE2024

Real-world data on growth hormone therapy adherence using a connected injection device and catch-up growth in children with growth disorders in Serbia

Zdravkovic Vera , Vorgucin Ivana , Stankovic Sandra , Milenkovic Tatjana , Cvetkovic Zoran , Koledova Ekaterina , van Dommelen Paula

Background: Recombinant human growth hormone (r-hGH) therapy is an effective treatment strategy for children experiencing growth disorders. However, poor adherence to long-term r-hGH therapy can lead to suboptimal catch-up growth. Digital health solutions, such as easypod® connect ecosystem, can facilitate adherence to r-hGH therapy in these patients.Aim: To investigate the adherence to r-hGH therapy administered via...